tbuckley/cabot-search huggingface dataset:
TCT-89 Morphological Characteristics of Thin-Cap Fibroatheroma Lesions in Patients With and Without Future Adverse Events: Insights From the COMBINE (OCT-FFR) Study
Authors: Magda Roleder-Dylewska, Pawel Gasior, Tomasz Roleder, Jaryl Ng, Ang Huiying, Rik Hermanides, Enrico Fabris, Alexander Ijsselmuiden, Floris Kauer, Fernando Alfonso, Clemens von Birgelen, Javier Escaned, Cyril Camaro, Bruno Pereira, Michael Magro, Holger Nef, Krzysztof Malinowski, Hector Garcia-Garcia, Juan Granada, Giuseppe De Luca, Mark Kennedy, Wojciech Wojakowski, Elvin Kedhi
Journal: Journal of the American College of Cardiology (2021)
TCT-2 Changes in Left Ventricular Global Longitudinal Strain in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT trial
Authors: Stephan Milhorini Pio, Diego Medvedofsky, Victoria Delgado, Farnaz Namazi, Neil Weissman, Paul Grayburn, Saibal Kar, Scott Lim, Zhipeng Zhou, Mengdan Liu, Maria Alu, Bjorn Redfors, Samir Kapadia, JoAnn Lindenfeld, William Abraham, Michael Mack, Federico Asch, Gregg Stone, Jeroen Bax
Journal: Journal of the American College of Cardiology (2021)
Glucose Abnormalities in Patients with Hepatitis C Virus Infection
Authors: Albert Lecube, Cristina Hernández, Joan Genescà, Rafael Simó
Journal: Diabetes Care (2006)

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, affecting ∼3% of the world’s population (1,2). The disease is characterized by silent onset in most infected individuals (3), and recent studies indicate that the rate of progression to advanced liver disease might be lower than previously assumed (4–6). If we consider that most HCV-infected persons are <50 years of age, the burden of disease associated with HCV infection is likely to increase during the next 10–20 years as this cohort reaches the age at which complications of chronic liver disease typically occur (7).

The prevalence of type 2 diabetes in people living in the developed world ranges from 2.0 to 9.4% (8), rising to 12.3% in U.S. adults between 40 and 74 years of age (9). The decline in mortality of people with diabetes, together with the rapidly increasing frequency of obesity and the sedentary lifestyle of the population portends a dramatic increase in the prevalence rates of type 2 diabetes (10–11). Therefore, both HCV liver disease and type 2 diabetes are two already prevalent diseases that will probably continue to increase in the next decades.

HCV mainly affects the liver, but also several tissues outside the liver have been reported to be involved, resulting in a wide spectrum of extrahepatic manifestations (12–14). During the last decade, it has been hypothesized that diabetes could be one more of these extrahepatic conditions attributable to HCV infection. This raises the intriguing question of whether the rise in HCV infection is contributing to the increasing prevalence of type 2 diabetes.

In this review, the available information concerning the epidemiological association between HCV infection and diabetes is summarized. In addition, the physiopathological mechanisms related to the association between HCV and diabetes …
TCT-99 Clinical Outcomes in Patients With High Bleeding Risk and Bifurcations After Percutaneous Coronary Intervention With Resolute Onyx and 1-Month Dual Antiplatelet Therapy
Authors: Ajay Kirtane, David Kandzari, Azeem Latib, Elvin Kedhi, Roxana Mehran, Matthew Price, Daniel Simon, Alexandre Abizaid, Maria Parke, Te-Hsin Lung, Stephan Windecker, Gregg Stone
Journal: Journal of the American College of Cardiology (2021)
Randomised controlled trial to investigate the use of high-frequency airway oscillations as<b>t</b>raining to<b>i</b>mprove<b>d</b>yspno<b>e</b>a (TIDe) in COPD
Authors: Enya Daynes, Neil Greening, Sally J Singh
Journal: Thorax (2021)

Background Chronic obstructive pulmonary disease (COPD) is characterised by symptomatic dyspnoea and reduced exercise tolerance, in part as a result muscle weakness, for which inspiratory muscle training (IMT) may be useful. Excess mucus hypersecretion commonly coexists in COPD and may lead to reduce ventilation, further impacting on breathlessness. Devices for sputum clearance may be employed to aid mucus expectoration. This trial aimed to explore the effectiveness of a combined IMT and high-frequency airway oscillating (HFAO) device in the management of dyspnoea. Methods This was a double-blinded, randomised sham-controlled trial which recruited symptomatic patients with COPD. Patients were randomised to either a HFAO device (Aerosure) or sham device for 8 weeks, three times a day. The primary outcome was the Chronic Respiratory Questionnaire dyspnoea (CRQ-D) domain. Pre-specified subgroup analyses were performed including those with respiratory muscle weakness, excessive sputum and frequent exacerbators. Results 104 participants (68% men, mean (SD) age 69.75 years (7.41), forced expiratory volume in 1 s per cent predicted 48.22% (18.75)) were recruited to this study with 96 participants completing. No difference in CRQ-D was seen between groups (0·28, 95% CI −0.19 to 0.75, p=0.24), though meaningful improvements were seen over time in both groups (mean (SD) HFAO 0.45 (0.78), p&lt;0.01; sham 0.73 (1.09), p&lt;0.01). Maximal inspiratory pressure significantly improved in the HFAO group over sham (5.26, 95% CI 0.34 to 10.19, p=0.05). Similar patterns were seen in the subgroup analysis. Conclusion There were no statistical differences between the HFAO and the sham group in improving dyspnoea measured by the CRQ-D. Trial registration number ISRCTN45695543 .
TCT-82 Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events: Insights From the COMBINE FFR-OCT Trial
Authors: Enrico Fabris, Balazs Berta, Magda Roleder-Dylewska, Tomasz Roleder, Pawel Gasior, Rik Hermanides, Alexander Ijsselmuiden, Floris Kauer, Fernando Alfonso, Clemens von Birgelen, Javier Escaned, Cyril Camaro, Mark Kennedy, Michael Magro, Holger Nef, Krzysztof Malinowski, Giuseppe De Luca, Hector Garcia-Garcia, Juan Granada, Wojciech Wojakowski, Elvin Kedhi
Journal: Journal of the American College of Cardiology (2021)
The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1
Authors: Beatriz Sanchez-Solana, Dunrui Wang, Xiaolan Qian, Parthibane Velayoudame, Dhirendra K. Simanshu, Jairaj K. Acharya, Douglas R. Lowy
Journal: Molecular Cancer (2021)

DLC1, a tumor suppressor gene that is downregulated in many cancer types by genetic and nongenetic mechanisms, encodes a protein whose RhoGAP and scaffolding activities contribute to its tumor suppressor functions. The role of the DLC1 START (StAR-related lipid transfer; DLC1-START) domain, other than its binding to Caveolin-1, is poorly understood. In other START domains, a key function is that they bind lipids, but the putative lipid ligand for DLC1-START is unknown.Lipid overlay assays and Phosphatidylserine (PS)-pull down assays confirmed the binding of DLC1-START to PS. Co-immunoprecipitation studies demonstrated the interaction between DLC1-START and Phospholipase C delta 1 (PLCD1) or Caveolin-1, and the contribution of PS to those interactions. Rho-GTP, cell proliferation, cell migration, and/or anchorage-independent growth assays were used to investigate the contribution of PS and PLCD1, or the implications of TCGA cancer-associated DLC1-START mutants, to DLC1 functions. Co-immunoprecipitations and PS-pull down assays were used to investigate the molecular mechanisms underlying the impaired functions of DLC1-START mutants. A structural model of DLC1-START was also built to better understand the structural implications of the cancer-associated mutations in DLC1-START.We identified PS as the lipid ligand for DLC1-START and determined that DLC1-START also binds PLCD1 protein in addition to Caveolin-1. PS binding contributes to the interaction of DLC1 with Caveolin-1 and with PLCD1. The importance of these activities for tumorigenesis is supported by our analysis of 7 cancer-associated DLC1-START mutants, each of which has reduced tumor suppressor function but retains wildtype RhoGAP activity. Our structural model of DLC1-START indicates the mutants perturb different elements within the structure, which is correlated with our experimental findings that the mutants are heterogenous with regard to the deficiency of their binding properties. Some have reduced PS binding, others reduced PLCD1 and Caveolin-1 binding, and others are deficient for all of these properties.These observations highlight the importance of DLC1-START for the tumor suppressor function of DLC1 that is RhoGAP-independent. They also expand the versatility of START domains, as DLC1-START is the first found to bind PS, which promotes the binding to other proteins.
Spatiotemporally controlled, aptamers-mediated growth factor release locally manipulates microvasculature formation within engineered tissues
Authors: Deepti Rana, Ajoy Kandar, Nasim Salehi-Nik, Ilyas Inci, Bart Koopman, Jeroen Rouwkema
Journal: Bioactive Materials (2021)

Spatiotemporally controlled growth factor (GF) delivery is crucial for achieving functional vasculature within engineered tissues. However, conventional GF delivery systems show inability to recapitulate the dynamic and heterogeneous nature of developing tissue's biochemical microenvironment. Herein, an aptamer-based programmable GF delivery platform is described that harnesses dynamic affinity interactions for facilitating spatiotemporal control over vascular endothelial GF (VEGF165) bioavailability within gelatin methacryloyl matrices. The platform showcases localized VEGF165 sequestration from the culture medium (offering spatial-control) and leverages aptamer-complementary sequence (CS) hybridization for triggering VEGF165 release (offering temporal-control), without non-specific leakage. Furthermore, extensive 3D co-culture studies (human umbilical vein-derived endothelial cells & mesenchymal stromal cells), in bi-phasic hydrogel systems revealed its fundamentally novel capability to selectively guide cell responses and manipulate lumen-like microvascular networks via spatiotemporally controlling VEGF165 bioavailability within 3D microenvironment. This platform utilizes CS as an external biochemical trigger for guiding vascular morphogenesis which is suitable for creating dynamically controlled engineered tissues.
TCT-264 Role of Renal Denervation in Hypertension: An Updated Meta-Analysis of Randomized Sham Controlled Trials
Authors: Amit Rout, Aakash Garg, Sarabjeet Suri, Ayush Arora, Shengnan Zheng, Abigail Chan, Vikas Singh
Journal: Journal of the American College of Cardiology (2021)
Routine Vaccination Coverage — Worldwide, 2020
Authors: Pierre Muhoza, M. Carolina Danovaro-Holliday, Mamadou S. Diallo, Padraic Murphy, Samir V. Sodha, Jennifer H. Requejo, Aaron S. Wallace
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Endorsed by the World Health Assembly in 2020, the Immunization Agenda 2030 (IA2030) strives to reduce morbidity and mortality from vaccine-preventable diseases across the life course (1). This report, which updates a previous report (2), presents global, regional,* and national vaccination coverage estimates and trends as of 2020. Changes are described in vaccination coverage and the numbers of unvaccinated and undervaccinated children as measured by receipt of the first and third doses of diphtheria, tetanus, and pertussis-containing vaccine (DTP) in 2020, when the COVID-19 pandemic began, compared with 2019. Global estimates of coverage with the third dose of DTP (DTP3) and a polio vaccine (Pol3) decreased from 86% in 2019 to 83% in 2020. Similarly, coverage with the first dose of measles-containing vaccine (MCV1) dropped from 86% in 2019 to 84% in 2020. The last year that coverage estimates were at 2020 levels was 2009 for DTP3 and 2014 for both MCV1 and Pol3. Worldwide, 22.7 million children (17% of the target population) were not vaccinated with DTP3 in 2020 compared with 19.0 million (14%) in 2019. Children who did not receive the first DTP dose (DTP1) by age 12 months (zero-dose children) accounted for 95% of the increased number. Among those who did not receive DTP3 in 2020, approximately 17.1 million (75%) were zero-dose children. Global coverage decreased in 2020 compared with 2019 estimates for the completed series of Haemophilus influenzae type b (Hib), hepatitis B vaccine (HepB), human papillomavirus vaccine (HPV), and rubella-containing vaccine (RCV). Full recovery from COVID-19-associated disruptions will require targeted, context-specific strategies to identify and catch up zero-dose and undervaccinated children, introduce interventions to minimize missed vaccinations, monitor coverage, and respond to program setbacks (3).
Cellular and systemic energy metabolic dysregulation in asthma development—a hypothesis-generating approach
Authors: Sergejs Berdnikovs, Dawn C. Newcomb, Tebeb Gebretsadik, Brittney M. Snyder, Derek A. Wiggins, Kadijah S. Poleon, Tina V. Hartert
Journal: Journal of Allergy and Clinical Immunology (2021)
TCT-277 Trend in The Utilization of Intravascular Ultrasound and Optical Coherence Tomography in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion: 4-Year Perspective
Authors: Arish Maknojia, Aamir Gilani, Abhijit Ghatak
Journal: Journal of the American College of Cardiology (2021)
Improving the radiopacity of Fe–Mn biodegradable metals by magnetron-sputtered W–Fe–Mn–C coatings: Application for thinner stents
Authors: Samira Ravanbakhsh, Carlo Paternoster, Gianni Barucca, Paolo Mengucci, Sofia Gambaro, Theophraste Lescot, Pascale Chevallier, Marc-André Fortin, Diego Mantovani
Journal: Bioactive Materials (2021)
TCT-132 Short- and Long-Term Performance of Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
Authors: Ahmad Mahmoud, Joshua Kramer, Yasmeen Taha, Mohammad Al-Ani, Joseph Larocca, Mohammed Elzeneini, Carl Pepine, Ki Park, Karen Smith, Calvin Choi
Journal: Journal of the American College of Cardiology (2021)
Current Marijuana Use and Alcohol Consumption Among Adults Following the Legalization of Nonmedical Retail Marijuana Sales — Colorado, 2015–2019
Authors: Kacy A. Crawford, Jacqueline A. Gardner, Elisabeth A. Meyer, Katelyn E. Hall, Dahsan S. Gary, Marissa B. Esser
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

In Colorado, excessive alcohol use* contributed to $5 billion in economic costs in 2010 (1) and >1,800 deaths annually during 2011-2015 (2). The most common pattern of excessive drinking is binge drinking (consumption of four or more drinks on an occasion for women or five or more drinks for men) (3), which is associated with increased likelihood of using other substances, including marijuana (4). Retail (i.e., nonmedical) marijuana sales began in Colorado on January 1, 2014. The Colorado Department of Public Health and Environment (CDPHE) and CDC used data from Colorado's 2015-2019 Behavioral Risk Factor Surveillance System (BRFSS) to examine current use of marijuana (including hashish) by drinking patterns among 45,991 persons aged ≥18 years who responded to questions about alcohol and marijuana use. The age-standardized, weighted prevalence of current marijuana use among persons who reported binge drinking (34.4%) was significantly higher than the prevalence among current non-binge drinkers (14.8%) and nondrinkers (9.9%). Evidence-based strategies recommended by the Community Preventive Services Task Force to reduce excessive alcohol use and tobacco use (e.g., increasing prices or reducing access) can reduce alcohol- and tobacco-related harms. Similar strategies might be effective in reducing marijuana use and its potential harms as well.
Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021
Authors: Silvia Stringhini, María-Eugenia Zaballa, Nick Pullen, Javier Perez-Saez, Carlos de Mestral, Andrea Jutta Loizeau, Julien Lamour, Francesco Pennacchio, Ania Wisniak, Roxane Dumont, Hélène Baysson, Viviane Richard, Elsa Lorthe, Claire Semaani, Jean-François Balavoine, Didier Pittet, Nicolas Vuilleumier, François Chappuis, Omar Kherad, Andrew S. Azman, Klara Posfay-Barbe, Laurent Kaiser, Idris Guessous
Journal: Eurosurveillance (2021)

Background Up-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions. Aim We estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign. Methods We conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies). Results Among 3,355 individuals (54.1% women; 20.8% aged &lt; 18 years and 13.4% aged ≥ 65 years), 2,161 (64.4%) had anti-S antibodies and 906 (27.0%) had anti-N antibodies. The total seroprevalence was 66.1% (95% credible interval (CrI): 64.1–68.0). We estimated that 29.9% (95% Crl: 28.0–31.9) of the population developed antibodies after infection; the rest having developed antibodies via vaccination. Seroprevalence estimates differed markedly across age groups, being lowest among children aged 0–5 years (20.8%; 95% Crl: 15.5–26.7) and highest among older adults aged ≥ 75 years (93.1%; 95% Crl: 89.6–96.0). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with higher educational level. Conclusion Most of the population has developed anti-SARS-CoV-2 antibodies, despite most teenagers and children remaining vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and to minimise spread among children.
TCT-336 Impact of Frailty on Outcomes After Transcatheter Mitral Valve Repair With MitraClip: Analysis From the National Inpatient Sample Database
Authors: Saul Rios, Weijia Li, Mohammad Mustehsan, Chengyue Jin, Adarsh Katamreddy, Yuhei Kobayashi, Azeem Latib
Journal: Journal of the American College of Cardiology (2021)
Deficiency of Tlr4 Homologue Rp105 Aggravates Outward Remodelling in a Murine Model of Arteriovenous Fistula Failure
Authors: T. Bezhaeva, C.Y. Wong, M.R. de Vries, E.P. van der Veer, C.M.A. van Alem, J.I. Rotmans, P.H.A. Quax
Journal: Circulation (2016)
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Authors: Chunlong Ma, Haozhou Tan, Juliana Choza, Yuyin Wang, Jun Wang
Journal: Acta Pharmaceutica Sinica B (2021)

SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target specificity and the cellular target engagement of the claimed Mpro inhibitors, we systematically characterize their mechanism of action using the cell-free FRET assay, the thermal shift-binding assay, the cell lysate Protease-Glo luciferase assay, and the cell-based FlipGFP assay. Collectively, our results have shown that majority of the Mpro inhibitors identified from drug repurposing including ebselen, carmofur, disulfiram, and shikonin are promiscuous cysteine inhibitors that are not specific to Mpro, while chloroquine, oxytetracycline, montelukast, candesartan, and dipyridamole do not inhibit Mpro in any of the assays tested. Overall, our study highlights the need of stringent hit validation at the early stage of drug discovery.
Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020
Authors: Maximilian Muenchhoff, Alexander Graf, Stefan Krebs, Caroline Quartucci, Sandra Hasmann, Johannes C Hellmuth, Clemens Scherer, Andreas Osterman, Stephan Boehm, Christopher Mandel, Andrea Sabine Becker-Pennrich, Michael Zoller, Hans Christian Stubbe, Stefan Munker, Dieter Munker, Katrin Milger, Madeleine Gapp, Stephanie Schneider, Adrian Ruhle, Linda Jocham, Leo Nicolai, Kami Pekayvaz, Tobias Weinberger, Helga Mairhofer, Elham Khatamzas, Katharina Hofmann, Patricia M Spaeth, Sabine Bender, Stefan Kääb, Bernhard Zwissler, Julia Mayerle, Juergen Behr, Michael von Bergwelt-Baildon, Martin Reincke, Beatrice Grabein, Christian Ludwig Hinske, Helmut Blum, Oliver T Keppler
Journal: Eurosurveillance (2021)

Background In the SARS-CoV-2 pandemic, viral genomes are available at unprecedented speed, but spatio-temporal bias in genome sequence sampling precludes phylogeographical inference without additional contextual data. Aim We applied genomic epidemiology to trace SARS-CoV-2 spread on an international, national and local level, to illustrate how transmission chains can be resolved to the level of a single event and single person using integrated sequence data and spatio-temporal metadata. Methods We investigated 289 COVID-19 cases at a university hospital in Munich, Germany, between 29 February and 27 May 2020. Using the ARTIC protocol, we obtained near full-length viral genomes from 174 SARS-CoV-2-positive respiratory samples. Phylogenetic analyses using the Auspice software were employed in combination with anamnestic reporting of travel history, interpersonal interactions and perceived high-risk exposures among patients and healthcare workers to characterise cluster outbreaks and establish likely scenarios and timelines of transmission. Results We identified multiple independent introductions in the Munich Metropolitan Region during the first weeks of the first pandemic wave, mainly by travellers returning from popular skiing areas in the Alps. In these early weeks, the rate of presumable hospital-acquired infections among patients and in particular healthcare workers was high (9.6% and 54%, respectively) and we illustrated how transmission chains can be dissected at high resolution combining virus sequences and spatio-temporal networks of human interactions. Conclusions Early spread of SARS-CoV-2 in Europe was catalysed by superspreading events and regional hotspots during the winter holiday season. Genomic epidemiology can be employed to trace viral spread and inform effective containment strategies.